Skip to content

The Efficacy and Tolerability of 12-weeks Treatment With Almond and Buckwheat Based Formula in Pediatric Patients With Active EoE

An Open Label, Pilot Study Assessing the Efficacy and Tolerability of 12-weeks Treatment With Almond and Buckwheat Based Formula in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05622214
Enrollment
20
Registered
2022-11-18
Start date
2022-07-25
Completion date
2023-12-31
Last updated
2022-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic Esophagitis

Brief summary

Eosinophilic esophagitis (EoE) is a chronic, relapsing, immune-mediated esophageal disease. Clinical manifestations in infants and toddlers generally include vomiting, food refusal, choking with meals and, less commonly, failure to thrive. The management of the disease includes dietary and pharmaceutical interventions, and the goal of the treatment should ideally be both the resolution of symptoms and the normalization of the macroscopic and microscopic abnormalities. Milk is the most common food trigger identified, followed by wheat, soy, and eggs. The aim of the study is to examine the tolerability of a new plant based formula made of minimally processed almond and buckwheat and enriched with vitamins and minerals.

Interventions

DIETARY_SUPPLEMENTElse nutrition formula

Plant based nutrition from almond and buckwheat

Sponsors

Else Nutrition GH Ltd
CollaboratorINDUSTRY
Rambam Health Care Campus
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Pediatric patients with active EoE (naïve and experienced) * Ages 1-18 years

Exclusion criteria

* Change in dosing of Proton pump inhibitors (PPI) medication * Local steroid treatment \< 1 month * Refusal to comply with study protocol * Known allergy to almonds and buckwheat * Use of dairy during the study

Design outcomes

Primary

MeasureTime frameDescription
Improvement in Pediatric Eosinophilic Esophagitis Symptom Severity Module (PEESS), endoscopic and histological scoring12 weeksImprovement in PEESS, endoscopic and histological scoring (assessed at week 0 and week 12)

Countries

Israel

Contacts

Primary ContactRon Shaoul, Dr.
r_shaoul@rambam.health.gov.il+972-4-7774381
Backup ContactLiat Pritzker
l_perel@rambam.health.gov.il+972-4-7774381

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026